White Papers

In “Aggregated Precision Investment: Strengths, Weaknesses, and Potential Paths Forward,” Rebecca Nielsen, Brooke Zollinger, and Sarah Johnson from Leavitt Partners explore the feasibility of operationalizing an aggregated precision investment (API) model for social determinants of health (SDOH) interventions. The authors derive their findings from subject matter expert interviews, conversations with potential aggregators, and relevant secondary research. This article enumerates … Continue reading

Featured Experts

Data science and digital health in clinical development and operations: impact, challenges, and calls to action for the drug development ecosystem In this paper, the Medicines Development Modernization Initiative discuss how three medicines development tools (MDTs) – artificial intelligence (AI) and machine learning (ML) algorithms, digital health tools (DHTs), and augmentation of randomized controlled trial … Continue reading

Pharmacy provision of clinical services is important to patient access and outcomes. As patients access more services from pharmacies, the data interoperability of those pharmacies becomes more important to the healthcare system at-large. Pharmacy teams’ ability to provide optimal care and meaningfully contribute to the value-based care transformation depends on their ability to access and … Continue reading

Today, Leavitt Partners, an HMA Company released a report outlining steps federal and state policymakers, technology and electronic health record (EHR) companies, health plans, pharmacies, and other healthcare providers can take to strengthen pharmacy data interoperability. As patients access more services from pharmacies, the data interoperability of those pharmacies becomes increasingly important to patients and … Continue reading

A RevCycleIntelligence article entitled “CMS Targets Value-Based Purchasing, Drug Costs to Reduce Spending” references the Leavitt Partners “Accountable Care Organizations and Risk-Based Payment Arrangements: Strong Preference for Upside-Only Contracts” white paper. The article states, “About 61 percent of ACO contracts contain only upside financial risk, meaning organizations do not have to repay financial losses, a … Continue reading

Digital health has experienced a rapid transformation in the last two years since the beginning of the COVID-19 pandemic, dramatically shifting how care is delivered to patients. To better understand the rapid changes occurring in the industry and capitalize on future market movements, Leavitt Partners has created a digital health taxonomy and standardized definitions, along with robust market segmentations and … Continue reading

Leavitt Partners examined publicly available resources to determine the 340B Drug Pricing Program’s (340B) impact on drug prices charged by both covered entities and pharmaceutical manufacturers. To answer these questions, Leavitt Partners undertook a comprehensive literature review of publicly available governmental reports, peer-reviewed journal articles, white papers, news articles, and other publicly available sources to … Continue reading

Nonadherence to a prescribed medication regimen for patients with chronic pain is associated with overall lower health outcomes, including increased hospital admissions, costs, and morbidity (quantitative review here). Deviations in timing, dosage, frequency, or duration of medication—all components of noncompliance—can cause medical reactions, increased pain, and medication use disorders, and can ultimately lead to emergency care … Continue reading